Work

Pan-KRAS inhibition: unlocking broad-spectrum targeted therapy for KRAS-mutant cancers

Year: 2026

Type: article

Abstract: KRAS is a critical proto-oncogene and molecular switch that is frequently mutated in human cancers. Oncogenic mutations, primarily at codons 12, 13, and 61, lock KRAS into a GTP-bound active state, thus resulting in constitutive signaling through downstream effectors such as RAF and phosphoinositide

Source: Cancer Biology and Medicine

DOI: 10.20892/j.issn.2095-3941.2025.0612

Authors: Juanjuan Feng, Xuanzheng Xiao, Zhengke Lian, Ao Zhang, Xiufeng Pang

Institutions: East China Normal University, Xi'an Jiaotong University, Shanghai Jiao Tong University

Language: English

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,500